Clinigen says it has partnered with Mitsubishi Tanabe Pharma to initiate a Managed Access Program in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (ALS).
Read More
The US Food and Drug Administration has issued a green light for MT Pharma America’s Radicav, opening the door to the first new therapy for amyotrophic lateral sclerosis (ALS) in more than 20 years.
Read More
US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.
Read More
US regulators have agreed to review Mitsubishi Tanabe’s application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.
Read More
